RandyW Posted January 16, 2010 Share Posted January 16, 2010 Cancer drug Tarceva, made by OSI Pharmaceuticals (OSIP)has had its review period extended by the Food and Drug Administration. The FDA has extended the period for examination due to additional information on the drug supplied by OSIP. Tarceva is marketed by both OSI and Roche Holding’s Genentech unit. It is approved to treat small cell lung cancer after treatment with chemotherapy fails. Because of this, the drug is considered second-line. As of Friday, OSI in combination with Genentech announced that by April 18, they expect FDA action to be taken on the drug. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.